Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.
When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off. In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it. Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval.
We think all investors should try to buy and hold high quality multi-year winners. And highest quality companies can...